OBJECTIVE: Cognitive decline is a key characteristic of Huntington's disease (HD). This study aimed to investigate the diagnostic accuracy of a cognitive battery with six tests used by most HD research centers to assess cognitive impairment in HD. METHOD: In total, 106 HD patients in different disease stages with more (HD-CD, N = 30) and less cognitive impairments (HD-NC, N = 70) and 100 healthy controls (NC) were matched by age, sex, and education and were examined using a standardized protocol including cognitive, motor, and functional assessments. RESULTS: One-way between-groups analysis of variance showed that controls performed significantly better than HD patients and that HD-NC significantly outperformed HD-CD patients in all cognitive tests (NC > HD-NC > HD-CD), with all Games-Howell post-hoc tests p < .001. Analyses using area under the receiver-operating characteristic curve (AUC) disclosed the diagnostic accuracy of all tests included in the battery to discriminate between NC and HD patients with AUC ranging from 0.809 to 0.862 (all p < .001) and between HD-CD and HD-NC patients with AUC ranging from 0.833 to 0.899 (all p < .001). In both analysis, Stroop Color Naming Test showed the highest discriminative potential. Additional analyses showed that cognitive deficits in all domains progressed with disease duration. Moreover, cognitive performance correlated with the severity of motor and functional impairment (all p < .001) and with the Disease Burden Score regardless of disease duration and age. CONCLUSION: Our results indicate that the cognitive battery is a suitable tool for assessing cognitive impairment in HD.

Department of Interdisciplinary Pain Therapy Day Clinic Klinikum Erding Erding Germany

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Department of Neurology University Hospital of Ulm Ulm Germany

Department of Neuropsychiatry Huntington Center South kbo Isar Amper Klinikum Taufkirchen Germany

Zobrazit více v PubMed

Alexander G. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience, 9(1), 357–381. PubMed

Andrew S. E., Goldberg Y. P., Kremer B., Telenius H., Theilmann J., Adam S.  et al. (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nature Genetics, 4(4), 398–403. PubMed

Baake V., Reijntjes R. H. A. M., Dumas E. M., Thompson J. C., Roos R. A. C., Bentivoglio A. R.  et al. (2017). Cognitive decline in Huntington’s disease expansion gene carriers. Cortex, 95, 51–62. PubMed

Bachoud Lévi A. C., Maison P., Bartolomeo P., Boissé M. F., Dalla Barba G., Ergis A. M.  et al. (2001). Retest effects and cognitive decline in longitudinal follow-up of patients with early HD. Neurology, 56(8), 1052–1058. PubMed

Beglinger L. J., Duff K., Allison J., Theriault D., O’Rourke J. J. F., & Leserman A. (2010). Cognitive change in patients with Huntington disease on the repeatable battery for the assessment of neuropsychological status. Journal of Clinical and Experimental Neuropsychology, 32(6), 573–578. PubMed PMC

Beglinger L. J., Prest L., Mills J. A., Paulsen J. S., Smith M. M., Gonzalez-Alegre P.  et al. (2012). Clinical predictors of driving status in Huntington’s disease. Movement Disorders, 27(9), 1146–1152. PubMed PMC

Benton A. L., & Hamsher K. (1989). Multilingual aphasia examination. Iowa City: AJA Associates.

Benton A. L., Hamsher K. D., Varney N. R., & Spreen O. (1994). Contributions to neuropsychological assessment: A clinical manual (2nd ed.). New York: Oxford University Press.

Bezdicek O., Majerova V., Novak M., Nikolai T., Ruzicka E., & Roth J. (2013). Validity of the Montreal cognitive assessment in the detection of cognitive dysfunction in Huntington’s disease. Applied Neuropsychology, 20(1), 33–40. PubMed

Bonelli R. M., & Cummings J. L. (2007). Frontal-subcortical circuitry and behavior. Dialogues in Clinical Neuroscience, 9(2), 141–151. PubMed PMC

Cohen J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Hillsdale, NJ: Lawrence Erlbaum Associates.

Duff K., Beglinger L. J., Theriault D., Allison J., & Paulsen J. S. (2010). Cognitive deficits in Huntington’s disease on the repeatable battery for the assessment of neuropsychological status. Journal of Clinical and Experimental Neuropsychology, 32(3), 231–238. PubMed PMC

Feigin A., Kieburtz K., Bordwell K., Como P., Steinberg K., Sotack J.  et al. (1995). Functional decline in Huntington’s disease. Movement Disorders, 10(2), 211–214. PubMed

Folstein M. F., Folstein S. E., & McHugh P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198. PubMed

Friesen D. C., Luo L., Luk G., & Bialystok E. (2015). Proficiency and control in verbal fluency performance across the lifespan for monolinguals and bilinguals. Language, Cognition and Neuroscience, 30(3), 238–250. PubMed PMC

Georgiou-Karistianis N., Gray M. A., Domínguez D., F J., Dymowski A. R., Bohanna I.  et al. (2013). Automated differentiation of pre-diagnosis Huntington’s disease from healthy control individuals based on quadratic discriminant analysis of the basal ganglia: The IMAGE-HD study. Neurobiology of Disease, 51, 82–92. PubMed

Giralt A., Saavedra A., Alberch J., & Pérez-Navarro E. (2012). Cognitive dysfunction in Huntington’s disease: humans, mouse models and molecular mechanisms. Journal of Huntington’s Disease, 1(2), 155–173. PubMed

Hanes K. R., Andrewes D. G., Pantelis C., & Chiu E. (1996). Subcortical dysfunction in schizophrenia: a comparison with Parkinson’s disease and Huntington’s disease. Schizophrenia Research, 19(2), 121–128. PubMed

Henry J. D., Crawford J. R., & Phillips L. H. (2005). A meta-analytic review of verbal fluency deficits in Huntington’s disease. Neuropsychology, 19(2), 243–252. PubMed

Homack S., & Riccio C. A. (2004). A meta-analysis of the sensitivity and specificity of the Stroop color and word test with children. Archives of Clinical Neuropsychology, 19(6), 725–743. PubMed

HSG (1996). Unified Huntington’s disease rating scale: reliability and consistency. Movement Disorders, 11(2), 136–142. PubMed

Huntington’s disease Collaborative Research Group (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell, 72(6), 971–983. PubMed

Katzev M., Tuscher O., Hennig J., Weiller C., & Kaller C. P. (2013). Revisiting the functional specialization of left inferior frontal Gyrus in phonological and semantic fluency: the crucial role of task demands and individual ability. Journal of Neuroscience, 33(18), 7837–7845. PubMed PMC

Kelland D. Z., & Lewis R. F. (1994). Evaluation of the reliability and validity of the repeatable cognitive-perceptual-motor battery. The Clinical Neuropsychologist, 8(3), 295–308.

Kirkwood S. C., Siemers E., Hodes M. E., Conneally P. M., Christian J. C., & Foroud T. (2000). Subtle changes among presymptomatic carriers of the Huntington’s disease gene. Journal of Neurology Neurosurgery & Psychiatry, 69(6), 773–779. PubMed PMC

Klempíř J., Klempířová O., Spačková N., Židovská J., & Roth J. (2006). Unified Huntington’s disease rating scale: clinical practice and a critical approach. Functional Neurology, 21(4), 217–221. PubMed

Klempíř J., Klempířová O., Štochl J., Špačková N., & Roth J. (2009). The relationship between impairment of voluntary movements and cognitive impairment in Huntington’s disease. Journal of Neurology, 256(10), 1629–1633. PubMed

Landwehrmeyer G. B., Fitzer-Attas C. J., Giuliano J. D., Gonçalves N., Anderson K. E., Cardoso F.  et al. (2017). Data analytics from Enroll-HD, a global clinical research platform for Huntington’s disease. Movement Disorders Clinical Practice, 4(2), 212–224. PubMed PMC

Larsen I. U., Vinther-Jensen T., Gade A., Nielsen J. E., & Vogel A. (2015). Assessing impairment of executive function and psychomotor speed in premanifest and manifest Huntington’s disease gene-expansion carriers. Journal of the International Neuropsychological Society, 21(3), 193–202. PubMed

Lawrence A. D., Sahakian B. J., Hodges J. R., & Rosser A. E. (1996). Executive and mneumonic functions in early Huntington’ s disease. Brain, 119, 1633–1645. PubMed

Lezak M. D., Howieson D. B., Bigler E. D., & Tranel D. (2012). Neuropsychological assessment (5th ed.). New York, NY: Oxford University Press.

Long J. D., Paulsen J. S., Marder K., Zhang Y., Kim J.-I., & Mills J. A. (2014). Tracking motor impairments in the progression of Huntington’s disease. Movement Disorders, 29(3), 311–319. PubMed PMC

Mestre T. A., Bachoud-Lévi A. C., Marinus J., Stout J. C., Paulsen J. S., Como P.  et al. (2018). Rating scales for cognition in Huntington’s disease: Critique and recommendations. Movement Disorders, 33(2), 187–195. PubMed PMC

Morris J. C., Heyman A., Mohs R. C., Hughes J. P., Belle G., Fillenbaum G.  et al. (1989). The consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. clinical and neuropsychological assessment of Alzheimer’s disease. Neurology, 39(9), 1159–1165. PubMed

Nopoulos P. C., Aylward E. H., Ross C. A., Mills J. A., Langbehn D. R., Johnson H. J.  et al. (2011). Smaller intracranial volume in prodromal Huntington’s disease: evidence for abnormal neurodevelopment. Brain, 134(1), 137–142. PubMed PMC

Paulsen J. S. (2011). Cognitive impairment in Huntington disease: diagnosis and treatment. Current Neurology and Neuroscience Reports, 11(5), 474–483. PubMed PMC

Paulsen J. S., & Long J. D. (2014). Onset of Huntington’s disease: can it be purely cognitive?  Movement Disorders, 29(11), 1342–1350. PubMed PMC

Paulsen J. S., Long J. D., Ross C. A., Harrington D. L., Erwin C. J., Williams J. K.  et al. (2014). Prediction of manifest Huntington’s disease with clinical and imaging measures: a prospective observational study. Lancet Neurology, 13(12), 1193–1201. PubMed PMC

Paulsen J. S., Miller A. C., Hayes T., & Shaw E. (2017). Cognitive and behavioral changes in Huntington disease before diagnosis In Handbook of Clinical Neurology (Vol. 144, pp. 69–91). 10.1016/B978-0-12-801893-4.00006-7 PubMed DOI

Paulsen J. S., Smith M. M., & Long J. D. (2013). Cognitive decline in prodromal Huntington disease: implications for clinical trials. Journal of Neurology, Neurosurgery and Psychiatry, 84(11), 1233–1239. PubMed PMC

Peavy G. M., Jacobson M. W., Goldstein J. L., Hamilton J. M., Kane A., Gamst A. C.  et al. (2010). Cognitive and functional decline in Huntington’s disease: dementia criteria revisited. Movement Disorders, 25(9), 1163–1169. PubMed PMC

Penney J. B., Vonsattel J. P., MacDonald M. E., Gusella J. F., & Myers R. H. (1997). CAG repeat number governs the development rate of pathology in huntington’s disease. Annals of Neurology, 41(5), 689–692. PubMed

Quarrell O. W., Nance M. A., Nopoulos P., Paulsen J. S., Smith J. A., & Squitieri F. (2013). Managing juvenile Huntington’s disease. Neurodegenerative Disease Management, 3(3), 267–276. PubMed PMC

Ready R. E., Mathews M., Leserman A., & Paulsen J. S. (2008). Patient and caregiver quality of life in Huntington’s disease. Movement Disorders, 23(5), 721–726. PubMed PMC

Reitan R. M. (1958). Validity of the trail making test as an indicator of organic brain damage. Perceptual and Motor Skills, 8(3), 271–276.

Ringkøbing S. P., Larsen I. U., Jørgensen K., Vinther-Jensen T., & Vogel A. (2020). Cognitive screening tests in Huntington gene mutation carriers: examining the validity of the mini-mental state examination and the Montreal cognitive assessment. Journal of Huntington’s Disease, 9, 59–68. PubMed

Roos R. A. C. (2010). Huntington’s disease: a clinical review. Orphanet Journal of Rare Diseases, 5(1), 40. PubMed PMC

Ross C. A., Pantelyat A., Kogan J., & Brandt J. (2014). Determinants of functional disability in Huntington’s disease: role of cognitive and motor dysfunction. Movement Disorders, 29(11), 1351–1358. PubMed PMC

Rosser A., & Hodges J. R. (1994). Initial letter and semantic category fluency in Alzheimer’s disease, Huntington’s disease, and progressive supranuclear palsy. Journal of Neurology, Neurosurgery, and Psychiatry, 57(11), 1389–1394. PubMed PMC

Rüb U., Vonsattel J. P. G., Heinsen H., & Korf H. W. (2015). The neuropathology of Huntington’s disease: classical findings, recent developments and correlation to functional neuroanatomy In Advances in anatomy, embryology, and cell biology (, Vol. 217, pp. 1–146). Cham: Springer. PubMed

Sampedro F., Martínez-Horta S., Perez-Perez J., Horta-Barba A., Martin-Lahoz J., Alonso-Solís A.  et al. (2019). Widespread increased diffusivity reveals early cortical degeneration in Huntington disease. American Journal of Neuroradiology, 1–5. 10.3174/ajnr.A6168. PubMed DOI PMC

Sánchez-Cubillo I., Periáñez J. A., Adrover-Roig D., Rodríguez-Sánchez J. M., Ríos-Lago M., Tirapu J.  et al. (2009). Construct validity of the trail making test: role of task-switching, working memory, inhibition/interference control, and visuomotor abilities. Journal of the International Neuropsychological Society, 15(3), 438–450. PubMed

Shao Z., Janse E., Visser K., & Meyer A. S. (2014). What do verbal fluency tasks measure? Predictors of verbal fluency performance in older adults. Frontiers in Psychology, 5(772). 10.3389/fpsyg.2014.00772. PubMed DOI PMC

Smith A. (1982). Symbol digit modalities test (SDMT) manual (revised).. vol. c  Western Psychological Services; 10.1177/1352458511431076 DOI

Smith A. (1991). Symbol digit modalities test (SDMT). Neuropsychological Assessment, 379–381. 10.1037/t27513-000. DOI

Snowden J. S. (2017). The neuropsychology of Huntington’s disease. Archives of Clinical Neuropsychology, 32(7), 876–887. PubMed

Snowden J. S., Craufurd D., Griffiths H., Thompson J., & Neary D. (2001). Longitudinal evaluation of cognitive disorder in Huntington’s disease. Journal of the International Neuropsychological Society. 10.1017/S1355617701711046. PubMed DOI

Stout J. C., Paulsen J. S., Queller S., Solomon A. C., Whitlock K. B., Campbell J. C.  et al. (2011). Neurocognitive signs in prodromal Huntington disease. Neuropsychology, 25(1), 1–14. PubMed PMC

Stout J. C., Queller S., Baker K. N., Cowlishaw S., Sampaio C., Fitzer-Attas C.  et al. (2014). HD-CAB: a cognitive assessment battery for clinical trials in Huntington’s disease. Movement Disorders, 29(10), 1281–1288. PubMed

Stroop J. R. (1935). Studies of interference in serial verbal reactions. Journal of Experimental Psychology, 18(6), 643–662.

Thompson J. C., Poliakoff E., Sollom A. C., Howard E., Craufurd D., & Snowden J. S. (2010). Automaticity and attention in Huntington’s disease: When two hands are not better than one. Neuropsychologia, 48(1), 171–178. PubMed

Toh E. A., MacAskill M. R., Dalrymple-Alford J. C., Myall D. J., Livingston L., Macleod S. A.  et al. (2014). Comparison of cognitive and UHDRS measures in monitoring disease progression in Huntington’s disease: a 12-month longitudinal study. Translational Neurodegeneration, 3, 15 10.1186/2047-9158-3-15. PubMed DOI PMC

Treisman A., & Fearnley S. (1969). The Stroop test: selective attention to colours and words. Nature, 222(5192), 437–439. PubMed

Vugt J. P. P., Piet K. K. E., Vink L. J., Siesling S., Zwinderman A. H., Middelkoop H. A. M.  et al. (2004). Objective assessment of motor slowness in Huntington’s disease: clinical correlates and 2-year follow-up. Movement Disorders, 19(3), 285–297. PubMed

Zuccato C., Valenza M., & Cattaneo E. (2010). Molecular mechanisms and potential Therapeutical targets in Huntington’s disease. Physiological Reviews, 90(3), 905–981. PubMed